Pre-Close Period Update

Dechra Pharmaceuticals PLC
10 July 2006







Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Monday, 10 July 2006
                                                               Embargoed: 7.00am


                           Dechra Pharmaceuticals PLC
                            Pre-Close Period Update


Dechra Pharmaceuticals PLC ('the Group') issues the following pre-close update
ahead of publication of the Group's Preliminary results for the year ended 30
June 2006.

Product Development Update

The clinical trial work required to obtain regulatory approval for Vetoryl(R)
Capsules and Felimazole(R) Tablets in the USA is progressing according to plan.
As previously indicated, these trials are expected to be completed prior to the
end of 2007.

Towards the end of our financial year, Vetoryl(R) Capsules were launched in
France, Germany and the Benelux countries by our European Marketing Partner.
Although this only had a small impact on results in the financial year ended 30
June 2006, we anticipate that the contribution will be more substantial in 2007.

Current Trading

Trading in the second half of our financial year ended 30 June 2006 continued to
be encouraging with the Group achieving revenue growth of approximately 10.5%
for the year.

We continue to make solid progress across the business which is reflected in the
performance of both our Pharmaceuticals and Services Divisions and in-line with
management expectations.

Shareholders will be updated further at the time of the Group's Preliminary
Results scheduled for 5 September 2006.





Enquiries:
Ian Page, Chief Executive
Simon Evans, Group Finance Director                            Fiona Tooley, Director
Dechra Pharmaceuticals PLC                                     Citigate Dewe Rogerson Ltd
Tel: [phone]                                        Tel: [phone]
Mobile: [phone] (IP) or [phone] (SE)     Mobile: [phone]
www.dechra.com





                      This information is provided by RNS
            The company news service from the London Stock Exchange